Sigyn Therapeutics (SIGY) Total Liabilities (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Total Liabilities of $6.1 million for Q3 2025, up 10.26% sequentially from $5.5 million in Q2 2025, and up 39.14% YoY from $4.4 million in Q3 2024.
Sigyn Therapeutics (SIGY) Total Liabilities (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Total Liabilities for 10 years, with the latest figure at $6.1 million in Q3 2025.
- Quarterly Total Liabilities rose 39.14% year-over-year to $6.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $6.1 million (up 39.14% YoY) and the FY2024 annual result came in at $4.7 million, up 25.09% from the prior year.
- Total Liabilities rose to $6.1 million in Q3 2025 per SIGY's latest filing, from $5.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $6.1 million in Q3 2025 and troughed at $689213.0 in Q1 2021.
- A 5-year average of $3.1 million and a median of $3.4 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2023: Total Liabilities sank 78.48% in 2021, then jumped 155.01% in 2023.
- Over 5 years, Total Liabilities stood at $974843.0 in 2021, then jumped by 129.38% to $2.2 million in 2022, then surged by 67.0% to $3.7 million in 2023, then rose by 25.09% to $4.7 million in 2024, then increased by 29.57% to $6.1 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $6.1 million, $5.5 million, and $5.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6.05 Mn |
| Jun 30, 2025 | 5.49 Mn |
| Mar 31, 2025 | 5.19 Mn |
| Dec 31, 2024 | 4.67 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | 3.99 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Dec 31, 2023 | 3.73 Mn |
| Sep 30, 2023 | 3.96 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.01 Mn |
| Dec 31, 2022 | 2.24 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 974,843.00 |
| Sep 30, 2021 | 1.08 Mn |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 689,213.00 |
| Dec 31, 2020 | 594,903.00 |